000118957 001__ 118957
000118957 005__ 20240319081010.0
000118957 0247_ $$2doi$$a10.3390/vaccines10071154
000118957 0248_ $$2sideral$$a130319
000118957 037__ $$aART-2022-130319
000118957 041__ $$aeng
000118957 100__ $$0(orcid)0000-0003-2313-2762$$aHernández-García, I.
000118957 245__ $$aInfluenza vaccination coverage among multiple sclerosis patients: evolution over time and associated factors
000118957 260__ $$c2022
000118957 5060_ $$aAccess copy available to the general public$$fUnrestricted
000118957 5203_ $$aOur objective was to determine the influenza vaccination rate in a Spanish cohort of multiple sclerosis (MS) patients. A retrospective cohort study was carried out. Patients who attended the MS unit of the Lozano Blesa Hospital of Zaragoza between January 2015 and 2020 were included. The variables were obtained by reviewing the specialized and primary care records. Associations between receiving the vaccine in each flu season and the other variables were analyzed using bivariate analysis and multiple logistic regression models. A total of 260 patients were studied, with a median age of 31 years at the time of diagnosis. A total of 62.3% (162/260) were women. Vaccination coverage ranged from 20.4% in the 2015–2016 and 2016–2017 seasons to 41.5% in the 2019–2020 season (p = 0.000). Having been vaccinated in the previous season (ORa: 16.47–390.22; p = 0.000) and receiving a vaccination recommendation from the hospital vaccination unit (ORa: 2.44–3.96; p < 0.009) were associated with being vaccinated. The coverage is in an intermediate position compared to other countries. It is necessary to improve the referral system of these patients to the hospital vaccination unit because the information obtained by this service contributed to higher vaccination rates.
000118957 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000118957 590__ $$a7.8$$b2022
000118957 592__ $$a1.655$$b2022
000118957 591__ $$aMEDICINE, RESEARCH & EXPERIMENTAL$$b24 / 136 = 0.176$$c2022$$dQ1$$eT1
000118957 593__ $$aDrug Discovery$$c2022$$dQ1
000118957 591__ $$aIMMUNOLOGY$$b32 / 161 = 0.199$$c2022$$dQ1$$eT1
000118957 593__ $$aImmunology$$c2022$$dQ1
000118957 593__ $$aPharmacology (medical)$$c2022$$dQ1
000118957 593__ $$aPharmacology$$c2022$$dQ1
000118957 593__ $$aInfectious Diseases$$c2022$$dQ1
000118957 594__ $$a7.0$$b2022
000118957 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000118957 700__ $$0(orcid)0000-0002-1756-5492$$aGarcés Redondo, M.$$uUniversidad de Zaragoza
000118957 700__ $$aRodríguez-Montolio, J.$$uUniversidad de Zaragoza
000118957 700__ $$aBengoa-Urrengoechea, I.
000118957 700__ $$aEspinosa-Rueda, J.$$uUniversidad de Zaragoza
000118957 700__ $$0(orcid)0000-0001-9714-8105$$aAibar Remón, C.$$uUniversidad de Zaragoza
000118957 700__ $$aVaccine Working Group
000118957 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000118957 7102_ $$11011$$2615$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Medic.Prevent.Salud Públ.
000118957 773__ $$g10, 7 (2022), 1154 [12 pp.]$$tVaccines$$x2076-393X
000118957 8564_ $$s292743$$uhttps://zaguan.unizar.es/record/118957/files/texto_completo.pdf$$yVersión publicada
000118957 8564_ $$s2691756$$uhttps://zaguan.unizar.es/record/118957/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000118957 909CO $$ooai:zaguan.unizar.es:118957$$particulos$$pdriver
000118957 951__ $$a2024-03-18-15:05:16
000118957 980__ $$aARTICLE